Real-world therapeutic effectiveness of lorlatinib after alectinib in Japanese patients with ALK-positive non-small-cell lung cancer.

Cancer Sci · 2023 · PMC10236600 · PMID 36866958

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

These data could indicate a decreasing trend for the use of chemotherapy as second‐ or later‐line treatment after ALK TKI failure.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.